Chancery Nixes Injunction in Feud Over Akrimax Drug Rights
An Akrimax Pharmaceuticals LLC investor lost a bid Monday for a preliminary injunction freezing the status of the company and a drug license allegedly in play for $250 million or more,...To view the full article, register now.
Already a subscriber? Click here to view full article